Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818606 | 0.87 | PTGDR2 (0.42) | PTGDR2SMN1; SMN2LMNAL3MBTL1TSHR | |
| SCHEMBL13632764 | 0.83 | PTGDR2 (0.55) | PTGDR2SMN1; SMN2LMNAL3MBTL1TSHR | |
| SCHEMBL6170291 | 0.83 | PTGDR2 (0.41) | PTGDR2SMN1; SMN2LMNAL3MBTL1TSHR | |
| SCHEMBL4824841 | 0.81 | PTGDR2 (0.49) | PTGDR2SMN1; SMN2LMNAL3MBTL1TSHR | |
| SCHEMBL1716316 | 0.80 | PTGDR2 (0.45) | PTGDR2SMN1; SMN2LMNAL3MBTL1TSHR | |
| SCHEMBL3535607 | 0.77 | ALDH1A1 (0.45) | ALDH1A1POLB | |
| SCHEMBL11371205 | 0.76 | PTGDR2 (0.45) | PTGDR2SMN1; SMN2LMNAL3MBTL1TSHR | |
| SCHEMBL31053274 | 0.74 | KDM4E (0.50) | SMN1; SMN2LMNAL3MBTL1TSHRALDH1A1 | |
| SCHEMBL15270946 | 0.74 | KDM4E (0.50) | SMN1; SMN2LMNAL3MBTL1TSHRALDH1A1 | |
| SCHEMBL1856036 | 0.74 | PTGDR2 (0.70) | PTGDR2SMN1; SMN2LMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-7425629-B2 | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425629-B2 | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20070100142-A1 | Reacting 1-amino-2-hydroxy-indene with a first protecting group containing a leaving group, followed by acetylation to prepare a protected intermediate, reacting with trifluoromethyl substituted ketone, then with metal oxide, hydrolysis, esterification, reaction with amino-picoline | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070100142-A1 | Reacting 1-amino-2-hydroxy-indene with a first protecting group containing a leaving group, followed by acetylation to prepare a protected intermediate, reacting with trifluoromethyl substituted ketone, then with metal oxide, hydrolysis, esterification, reaction with amino-picoline | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | ENPP2, ATXN2, ATXN2L | PTGDR2 1976/4885SMN1; SMN2 599/4885LMNA 2206/4885 |
| US-20070100142-A1 | Reacting 1-amino-2-hydroxy-indene with a first protecting group containing a leaving group, followed by acetylation to prepare a protected intermediate, reacting with trifluoromethyl substituted ketone, then with metal oxide, hydrolysis, esterification, reaction with amino-picoline | ALDH7A1, AADAT, ALDH18A1 | PTGDR2 1217/4885SMN1; SMN2 4184/4885LMNA 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.